Published: 3 April 2021
Author(s): Yuan Lu, Fei Li, Yong Fan, Yu Yang, Minglong Chen, Jue Xi
Issue: May 2021
Section: Original article

Heart failure (HF) is a highly prevalent disease with considerable morbidity and mortality. It is estimated that approximately 50 million people are afflicted with this disease worldwide. The disease burden of HF represents one of the most serious health concerns facing society today (1, 2). Prognosis of HF remains unsatisfactory, and multiple comorbidities with HF impede therapeutic options. Among patients with HF, type 2 diabetes mellitus (T2DM) is a fairly common comorbidity that is present in 20–40% of all patients (3).


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.